Study: Maintaining the enzyme ACE2 in the gut prevents diabetic blindness
January 16th 2023Diabetic retinopathy is the leading cause of blindness in American adults, and a team of researchers believes the source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.
Read More
Singapore scientists discover novel therapeutic target to advance treatment of diabetic eye diseases
December 27th 2022According to investigators, the study demonstrated that by restoring the function of ADAM10, a major shedding protein, it was possible in preclinical models to control the abnormal formation of blood vessels, offering an attractive therapeutic target to treat DR.
Read More
EyeCon 2022: Important updates in retinopathy of prematurity for clinicians
December 17th 2022Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.
Read More
New potential mechanism for vision loss discovered
December 6th 2022Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
Read More
Retinal cells may have potential to protect themselves from diabetic retinopathy
December 5th 2022According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
Read More
SparingVision’s lead asset SPVN06 clears IND application in US for treatment of retinitis pigmentosa
December 4th 2022SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.
Read More